1.49
price down icon1.32%   -0.02
after-market After Hours: 1.56 0.07 +4.70%
loading
Okyo Pharma Limited stock is traded at $1.49, with a volume of 69,798. It is down -1.32% in the last 24 hours and up +39.91% over the past month. OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
See More
Previous Close:
$1.51
Open:
$1.5
24h Volume:
69,798
Relative Volume:
0.42
Market Cap:
$50.57M
Revenue:
-
Net Income/Loss:
$-13.27M
P/E Ratio:
-9.0854
EPS:
-0.164
Net Cash Flow:
$-7.70M
1W Performance:
+8.76%
1M Performance:
+39.91%
6M Performance:
+44.66%
1Y Performance:
+2.76%
1-Day Range:
Value
$1.39
$1.5799
1-Week Range:
Value
$1.31
$1.5799
52-Week Range:
Value
$0.8075
$1.90

Okyo Pharma Limited Stock (OKYO) Company Profile

Name
Name
Okyo Pharma Limited
Name
Phone
-
Name
Address
-
Name
Employee
3
Name
Twitter
Name
Next Earnings Date
2024-09-30
Name
Latest SEC Filings
Name
OKYO's Discussions on Twitter

Compare OKYO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
OKYO
Okyo Pharma Limited
1.49 50.57M 0 -13.27M -7.70M -0.164
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

Okyo Pharma Limited Stock (OKYO) Latest News

pulisher
Mar 10, 2025

OKYO Pharma seeks FDA fast track for eye pain treatment By Investing.com - Investing.com Australia

Mar 10, 2025
pulisher
Mar 10, 2025

OKYO Pharma seeks FDA Fast Track for eye pain drug By Investing.com - Investing.com Australia

Mar 10, 2025
pulisher
Mar 10, 2025

OKYO Pharma seeks FDA fast track for eye pain treatment - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

OKYO Pharma Seeks FDA Fast Track for Urcosimod in Treating Neuropathic Corneal Pain - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

OKYO Pharma seeks FDA Fast Track for eye pain drug - Investing.com

Mar 10, 2025
pulisher
Mar 10, 2025

OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain - GlobeNewswire

Mar 10, 2025
pulisher
Mar 10, 2025

OKYO Files FDA Fast Track Application for Breakthrough Eye Pain Drug - StockTitan

Mar 10, 2025
pulisher
Mar 10, 2025

OKYO Pharma seeks FDA Fast Track designation for neuropathic corneal pain treatment - Proactive Investors USA

Mar 10, 2025
pulisher
Mar 05, 2025

OKYO Pharma secures $1.4 million non-dilutive funding - MSN

Mar 05, 2025
pulisher
Mar 05, 2025

Comparing Immunovant (NASDAQ:IMVT) & OKYO Pharma (NASDAQ:OKYO) - Defense World

Mar 05, 2025
pulisher
Feb 20, 2025

OKYO Pharma advances neuropathic corneal pain drug trial - MSN

Feb 20, 2025
pulisher
Feb 19, 2025

OKYO Pharma (NASDAQ:OKYO) Receives “Buy” Rating from HC Wainwright - Defense World

Feb 19, 2025
pulisher
Feb 18, 2025

H.C. WAINWRIGHT MAINTAINS BUY RATING ON OKYO PHARMA STOCK By Investing.com - Investing.com Australia

Feb 18, 2025
pulisher
Feb 18, 2025

H.C. WAINWRIGHT MAINTAINS BUY RATING ON OKYO PHARMA STOCK - Investing.com India

Feb 18, 2025
pulisher
Feb 17, 2025

Contrasting OKYO Pharma (NASDAQ:OKYO) and CG Oncology (NASDAQ:CGON) - Defense World

Feb 17, 2025
pulisher
Feb 14, 2025

Buy Recommendation for OKYO Pharma Driven by Promising Urcosimod Efficacy and Market Potential - TipRanks

Feb 14, 2025
pulisher
Feb 14, 2025

Okyo Pharma's OK-101 renamed urcosimod for eye pain - MSN

Feb 14, 2025
pulisher
Feb 12, 2025

H.C. Wainwright maintains Buy on OKYO Pharma with $7 target - MSN

Feb 12, 2025
pulisher
Feb 12, 2025

OKYO Pharma’s lead asset receives USAN designation "urcosimod By Investing.com - Investing.com Nigeria

Feb 12, 2025
pulisher
Feb 12, 2025

OKYO Pharma's lead asset receives USAN designation "urcosimod - MSN

Feb 12, 2025
pulisher
Feb 12, 2025

OKYO Pharma has dry eyes as a lucrative prize in its sights - Proactive Investors UK

Feb 12, 2025
pulisher
Feb 12, 2025

Okyo Pharma's OK-101 renamed urcosimod for eye pain By Investing.com - Investing.com South Africa

Feb 12, 2025
pulisher
Feb 12, 2025

OKYO Pharma's lead asset receives USAN designation "urcosimod By Investing.com - Investing.com UK

Feb 12, 2025
pulisher
Feb 12, 2025

OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod - GlobeNewswire

Feb 12, 2025
pulisher
Feb 12, 2025

OKYO Pharma’s Lead Asset OK-101 Receives USAN as Urcosimod - TipRanks

Feb 12, 2025
pulisher
Feb 12, 2025

Okyo Pharma Limited Announces OK-101 Officially Assigned USAN : Urcosimod -February 12, 2025 at 07:01 am EST - Marketscreener.com

Feb 12, 2025
pulisher
Feb 12, 2025

Revolutionary Eye Drug Urcosimod Targets Two Major Unmet Medical Needs - StockTitan

Feb 12, 2025
pulisher
Feb 12, 2025

OKYO Pharma says OK-101 gains USAN reflecting role in ocular disease modulation - Proactive Investors USA

Feb 12, 2025
pulisher
Feb 11, 2025

H.C. Wainwright maintains Buy on OKYO Pharma with $7 target By Investing.com - Investing.com South Africa

Feb 11, 2025
pulisher
Feb 11, 2025

OKYO Pharma (NASDAQ:OKYO) Receives Buy Rating from HC Wainwright - Defense World

Feb 11, 2025
pulisher
Feb 10, 2025

Yi Chen’s Buy Recommendation on OKYO Pharma: Promising Potential of OK-101 for Neuropathic Corneal Pain Amid Financial and Regulatory Challenges - TipRanks

Feb 10, 2025
pulisher
Feb 03, 2025

OKYO Pharma Announces Chairman and CEO Acquire Shares -February 03, 2025 at 09:04 am EST - Marketscreener.com

Feb 03, 2025
pulisher
Feb 01, 2025

OKYO Pharma poised for multi-billion-dollar opportunity in ocular treatment market, analysts believe - Proactive Investors Australia

Feb 01, 2025
pulisher
Jan 31, 2025

OKYO Pharma Announces Chairman and CEO Acquire Shares -January 31, 2025 at 07:00 am EST - Marketscreener.com

Jan 31, 2025
pulisher
Jan 31, 2025

OKYO Pharma insiders buy shares amid clinical trials - MSN

Jan 31, 2025
pulisher
Jan 31, 2025

OKYO Pharma insiders acquire shares - Proactive Investors USA

Jan 31, 2025
pulisher
Jan 31, 2025

OKYO Pharma insiders buy shares amid clinical trials By Investing.com - Investing.com South Africa

Jan 31, 2025
pulisher
Jan 31, 2025

OKYO Pharma Executives Increase Shareholdings, Affirming Market Confidence - TipRanks

Jan 31, 2025
pulisher
Jan 31, 2025

OKYO Pharma Announces Chairman and CEO Acquire Shares - The Manila Times

Jan 31, 2025

Okyo Pharma Limited Stock (OKYO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Cap:     |  Volume (24h):